BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 22859960)

  • 1. Metabolic profiling in Maturity-onset diabetes of the young (MODY) and young onset type 2 diabetes fails to detect robust urinary biomarkers.
    Gloyn AL; Faber JH; Malmodin D; Thanabalasingham G; Lam F; Ueland PM; McCarthy MI; Owen KR; Baunsgaard D
    PLoS One; 2012; 7(7):e40962. PubMed ID: 22859960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
    Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
    Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.
    Besser RE; Shepherd MH; McDonald TJ; Shields BM; Knight BA; Ellard S; Hattersley AT
    Diabetes Care; 2011 Feb; 34(2):286-91. PubMed ID: 21270186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A decision algorithm to identify patients with high probability of monogenic diabetes due to HNF1A mutations.
    Szopa M; Klupa T; Kapusta M; Matejko B; Ucieklak D; Glodzik W; Zapala B; Sani CM; Hohendorff J; Malecki MT; Skupien J
    Endocrine; 2019 Apr; 64(1):75-81. PubMed ID: 30778899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights from basic adjunctive examinations of GCK-MODY, HNF1A-MODY, and type 2 diabetes: A systemic review and meta-analysis.
    Liu J; Xiao X; Zhang Q; Yu M
    J Diabetes; 2023 Jun; 15(6):519-531. PubMed ID: 37226652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maturity Onset Diabetes of the Young (MODY) in Tunisia: Low frequencies of GCK and HNF1A mutations.
    Ben Khelifa S; Martinez R; Dandana A; Khochtali I; Ferchichi S; Castaño L
    Gene; 2018 Apr; 651():44-48. PubMed ID: 29408271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.
    Thanabalasingham G; Shah N; Vaxillaire M; Hansen T; Tuomi T; Gašperíková D; Szopa M; Tjora E; James TJ; Kokko P; Loiseleur F; Andersson E; Gaget S; Isomaa B; Nowak N; Raeder H; Stanik J; Njolstad PR; Malecki MT; Klimes I; Groop L; Pedersen O; Froguel P; McCarthy MI; Gloyn AL; Owen KR
    Diabetologia; 2011 Nov; 54(11):2801-10. PubMed ID: 21814873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
    Pal A; Farmer AJ; Dudley C; Selwood MP; Barrow BA; Klyne R; Grew JP; McCarthy MI; Gloyn AL; Owen KR
    Diabetes Care; 2010 Feb; 33(2):252-7. PubMed ID: 19933992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations.
    Owen KR; Thanabalasingham G; James TJ; Karpe F; Farmer AJ; McCarthy MI; Gloyn AL
    Diabetes Care; 2010 Sep; 33(9):1919-24. PubMed ID: 20724646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-inheritance of HNF1a and GCK mutations in a family with maturity-onset diabetes of the young (MODY): implications for genetic testing.
    López-Garrido MP; Herranz-Antolín S; Alija-Merillas MJ; Giralt P; Escribano J
    Clin Endocrinol (Oxf); 2013 Sep; 79(3):342-7. PubMed ID: 23009393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating ghrelin level is higher in HNF1A-MODY and GCK-MODY than in polygenic forms of diabetes mellitus.
    Nowak N; Hohendorff J; Solecka I; Szopa M; Skupien J; Kiec-Wilk B; Mlynarski W; Malecki MT
    Endocrine; 2015 Dec; 50(3):643-9. PubMed ID: 25987348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults.
    Fendler W; Borowiec M; Antosik K; Szadkowska A; Deja G; Jarosz-Chobot P; Mysliwiec M; Wyka K; Pietrzak I; Skupien J; Malecki MT; Mlynarski W
    Clin Endocrinol (Oxf); 2011 Sep; 75(3):321-7. PubMed ID: 21521320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in HNF1A result in marked alterations of plasma glycan profile.
    Thanabalasingham G; Huffman JE; Kattla JJ; Novokmet M; Rudan I; Gloyn AL; Hayward C; Adamczyk B; Reynolds RM; Muzinic A; Hassanali N; Pucic M; Bennett AJ; Essafi A; Polasek O; Mughal SA; Redzic I; Primorac D; Zgaga L; Kolcic I; Hansen T; Gasperikova D; Tjora E; Strachan MW; Nielsen T; Stanik J; Klimes I; Pedersen OB; Njølstad PR; Wild SH; Gyllensten U; Gornik O; Wilson JF; Hastie ND; Campbell H; McCarthy MI; Rudd PM; Owen KR; Lauc G; Wright AF
    Diabetes; 2013 Apr; 62(4):1329-37. PubMed ID: 23274891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young.
    Thanabalasingham G; Pal A; Selwood MP; Dudley C; Fisher K; Bingley PJ; Ellard S; Farmer AJ; McCarthy MI; Owen KR
    Diabetes Care; 2012 Jun; 35(6):1206-12. PubMed ID: 22432108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maturity onset diabetes of the young (MODY) in Chinese children: genes and clinical phenotypes.
    Ming-Qiang Z; Yang-Li D; Ke H; Wei W; Jun-Fen F; Chao-Chun Z; Guan-Ping D
    J Pediatr Endocrinol Metab; 2019 Jul; 32(7):759-765. PubMed ID: 31216263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolite profiling reveals normal metabolic control in carriers of mutations in the glucokinase gene (MODY2).
    Spégel P; Ekholm E; Tuomi T; Groop L; Mulder H; Filipsson K
    Diabetes; 2013 Feb; 62(2):653-61. PubMed ID: 23139355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intima-media thickness and endothelial dysfunction in GCK and HNF1A-MODY patients.
    Szopa M; Osmenda G; Wilk G; Matejko B; Skupien J; Zapala B; Młynarski W; Guzik T; Malecki MT
    Eur J Endocrinol; 2015 Mar; 172(3):277-83. PubMed ID: 25501962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maturity-onset diabetes of the young (MODY) in Brazil: Establishment of a national registry and appraisal of available genetic and clinical data.
    Giuffrida FMA; Moises RS; Weinert LS; Calliari LE; Manna TD; Dotto RP; Franco LF; Caetano LA; Teles MG; Lima RA; Alves C; Dib SA; Silveiro SP; Dias-da-Silva MR; Reis AF;
    Diabetes Res Clin Pract; 2017 Jan; 123():134-142. PubMed ID: 28012402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth.
    Pihoker C; Gilliam LK; Ellard S; Dabelea D; Davis C; Dolan LM; Greenbaum CJ; Imperatore G; Lawrence JM; Marcovina SM; Mayer-Davis E; Rodriguez BL; Steck AK; Williams DE; Hattersley AT;
    J Clin Endocrinol Metab; 2013 Oct; 98(10):4055-62. PubMed ID: 23771925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
    McDonald TJ; Shields BM; Lawry J; Owen KR; Gloyn AL; Ellard S; Hattersley AT
    Diabetes Care; 2011 Aug; 34(8):1860-2. PubMed ID: 21700917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.